Skip to main
ALZN

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc., an early clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for neurodegenerative diseases and psychiatric disorders, with a strong focus on its promising pipeline candidates AL001 and AL002. The company has recently reported positive top-line results from its studies, which are expected to serve as significant catalysts for future stock performance. Additionally, the current valuation is viewed as attractive, with substantial upside potential identified through a net present value analysis, reflecting a favorable outlook for the company's financial growth.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, resulting in an earnings per share (EPS) of $(1.28), significantly worse than the estimated EPS of $(0.69). The company faces multiple risks that could hinder its financial performance, including liquidity challenges and the potential failure of its drug candidates to prove safety and efficacy during clinical trials. Additionally, the competitive landscape and obstacles in commercialization and regulatory approval could further complicate the company’s ability to secure reimbursement and market its products effectively.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.